LakeShore Biopharma Co., Ltd (LSBCF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

LakeShore Biopharma Co., Ltd (LSBCF) Healthcare & Pipeline Overview

LakeShore Biopharma Co., Ltd, formerly YS Biopharma, is a China-based biopharmaceutical company specializing in vaccines and therapeutic biologics. Its proprietary PIKA technology platform drives the development of products targeting infectious diseases and cancer, with operations spanning multiple countries including the United States and Singapore.

What Is the Investment Thesis for LSBCF?

LakeShore Biopharma Co., Ltd presents an investment opportunity within the biotechnology sector, driven by its proprietary PIKA immunomodulating technology platform. The company's focus on developing vaccines and therapeutic biologics for infectious diseases and cancer addresses critical global health needs. Key value drivers include the potential commercial success of its PIKA rabies vaccine and PIKA recombinant COVID-19 vaccine. The company's operations in multiple countries, including China, the United States, and Singapore, provide geographic diversification. However, the company's negative profit margin of -16.3% and listing on the OTC market present significant risks. Investors should carefully consider the regulatory landscape and competitive pressures within the biopharmaceutical industry.

Based on FMP financials and quantitative analysis

LSBCF Key Highlights

LakeShore Biopharma Co., Ltd operates with 758 employees, indicating a substantial operational scale for a biotechnology company.

• The company's gross margin of 82.5% suggests strong pricing power and efficient manufacturing processes within its product portfolio.
• LakeShore Biopharma Co., Ltd's negative P/E ratio of -0.33 reflects its current lack of profitability, requiring further investigation into its financial performance.
• The company's beta of 0.68 indicates lower volatility compared to the overall market, potentially offering a degree of stability for investors.
• LakeShore Biopharma Co., Ltd's focus on the PIKA immunomodulating technology platform represents a key differentiator in the competitive biotechnology landscape.

Who Are LSBCF's Competitors?

LSBCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LSBCF's Key Strengths?

Proprietary PIKA immunomodulating technology platform.

• Focus on high-growth markets for vaccines and biologics.
• Established presence in multiple countries.
• Experienced management team.

What Are LSBCF's Weaknesses?

Negative profit margin.

• Reliance on successful development and commercialization of pipeline products.
• Limited financial resources compared to larger competitors.
• OTC market listing may limit investor access.

What Could Drive LSBCF Stock Higher?

Clinical trial results for PIKA rabies vaccine expected in Q4 2026.

• Expansion of commercial operations into new geographic markets.
• Development of new PIKA-based products targeting infectious diseases and cancer.
• Potential strategic partnerships with pharmaceutical companies and research institutions by Q2 2027.
• Increased government funding for vaccine research and development initiatives.

What Are the Key Risks for LSBCF?

Financial-distress signal — its Altman Z-Score of -2.86 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-18.4%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 4 reported quarters.
• Regulatory hurdles and delays in obtaining approvals for new products.
• Intense competition from established pharmaceutical companies.
• Clinical trial failures and setbacks in product development.
• Dependence on successful commercialization of pipeline products.
• Limited financial resources and access to capital.

What Are the Growth Opportunities for LSBCF?

• Expansion of PIKA Technology: LakeShore Biopharma can leverage its proprietary PIKA immunomodulating technology platform to develop new vaccines and therapeutic biologics beyond its current pipeline. The global market for immunomodulatory drugs is projected to reach $200 billion by 2028, presenting a significant opportunity for LakeShore Biopharma to expand its product offerings and market share. Successful development and commercialization of new PIKA-based products could drive substantial revenue growth.
• Geographic Expansion: LakeShore Biopharma's current operations span China, the United States, Singapore, the United Arab Emirates, and the Philippines. Expanding into new geographic markets, particularly in Europe and Latin America, could unlock significant growth opportunities. These regions represent large and growing markets for vaccines and therapeutic biologics, offering LakeShore Biopharma the potential to diversify its revenue streams and reduce its reliance on existing markets.
• Strategic Partnerships: Collaborating with other pharmaceutical companies, research institutions, and government agencies can accelerate LakeShore Biopharma's research and development efforts and expand its commercial reach. Strategic partnerships can provide access to new technologies, funding, and distribution channels, enabling LakeShore Biopharma to bring its products to market more quickly and efficiently. Pursuing such alliances will be critical for sustained growth.
• Focus on Rabies Vaccine: LakeShore Biopharma's PIKA rabies vaccine represents a significant growth opportunity, particularly in regions with high incidence rates of rabies. The global rabies vaccine market is projected to reach $1 billion by 2027, driven by increasing awareness of the disease and government initiatives to promote vaccination. Successful commercialization of the PIKA rabies vaccine could generate substantial revenue for LakeShore Biopharma.
• COVID-19 Vaccine Development: The ongoing COVID-19 pandemic continues to drive demand for effective vaccines. LakeShore Biopharma's PIKA recombinant COVID-19 vaccine has the potential to capture a share of this market, particularly in regions where access to existing vaccines is limited. Continued development and clinical trials of the PIKA COVID-19 vaccine could position LakeShore Biopharma as a key player in the global fight against the pandemic.

What Are LSBCF's Competitive Advantages?

• Proprietary PIKA immunomodulating technology platform.
• Established manufacturing capabilities.
• Global operational footprint.
• Focus on addressing unmet medical needs in infectious diseases and cancer.

What Does LSBCF Do?

LakeShore Biopharma Co., Ltd, established in 2002 and headquartered in Beijing, China, is a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics. The company's core focus lies in addressing infectious diseases and cancer through innovative solutions. Its proprietary PIKA immunomodulating technology platform forms the backbone of its research and development efforts. This platform is designed to enhance the body's immune response, leading to more effective treatments and preventative measures. LakeShore Biopharma's product pipeline includes the PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001, each targeting significant unmet medical needs. The company's operational footprint extends beyond China, encompassing the United States, Singapore, the United Arab Emirates, and the Philippines, reflecting its global ambitions and reach. In May 2024, the company rebranded from YS Biopharma Co., Ltd to LakeShore Biopharma Co., Ltd, marking a new chapter in its corporate evolution. This change reflects the company's continued growth and strategic focus on becoming a leading player in the biopharmaceutical industry.

What Products and Services Does LSBCF Offer?

• Discovers and develops vaccines for infectious diseases.
• Develops therapeutic biologics for cancer treatment.
• Manufactures vaccines and biologics.
• Commercializes its products in multiple countries.
• Utilizes its proprietary PIKA immunomodulating technology platform.
• Targets diseases like rabies and COVID-19 with specific vaccine programs.
• Conducts research and clinical trials to advance its product pipeline.

How Does LSBCF Make Money?

• Develops and patents proprietary vaccine and biologic technologies.
• Generates revenue through the sale of vaccines and therapeutic biologics.
• Partners with distributors and healthcare providers to reach target markets.
• Invests in research and development to expand its product pipeline.

What Industry Does LSBCF Operate In?

LakeShore Biopharma Co., Ltd operates within the highly competitive biotechnology industry, characterized by rapid innovation and stringent regulatory requirements. Key competitors include companies focused on vaccine development and therapeutic biologics. LakeShore Biopharma's success depends on its ability to navigate the regulatory landscape, secure partnerships, and effectively commercialize its products. The company's PIKA technology platform offers a potential competitive advantage in this dynamic environment.

Who Are LSBCF's Key Customers?

• Government healthcare agencies.
• Hospitals and clinics.
• Individual patients.
• Vaccine distributors.

Company Profile

LakeShore Biopharma Co., Ltd operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Wang Xu. LSBCF has traded publicly since 2021.

LakeShore Biopharma Co., Ltd's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.86 places it in the distress zone, a signal of elevated financial risk.

Return on equity for LakeShore Biopharma Co., Ltd stands at -18.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.3%, showing how much profit it generates from its asset base. A current ratio of 1.02 indicates the company holds enough short-term assets to cover its near-term obligations.

LSBCF Valuation & Market Position

With a $3.00M market cap, LakeShore Biopharma Co., Ltd sits in the micro-cap segment of the market. Relative to its peer group, LSBCF's quantitative score of 57/100 is above the peer average of 46/100.

LakeShore Biopharma Co., Ltd has missed Wall Street's EPS estimate in 3 of its last 4 reported quarters — a mixed record worth weighing. Reported results have landed about 80.1% below estimates on average.

Wall Street analysts project LakeShore Biopharma Co., Ltd revenue of about $1.45B for fiscal 2026, with EPS near $10.07.

LSBCF Financials

LSBCF Latest News

LSBCF Analyst Consensus

LSBCF MoonshotScore

LSBCF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources